MTN-002

The first study of a candidate topical microbicide ever conducted in pregnant women, MTN-002 sought to understand whether tenofovir gel, which was being evaluated in trials to support its potential licensure, would be safe to use during pregnancy. The Phase I study involved giving a single dose of tenofovir gel to 16 healthy, HIV-negative women hours before they gave birth by scheduled Cesarean section. Results, reported in 2010, found only small amounts of drug were absorbed into the mother’s bloodstream, amniotic fluid and umbilical cord (fetal) blood; and no serious side effects in either the mothers or their newborns. (See also MTN-008.)

 

Researchers report results of first microbicide trial in pregnant women

Study indicates small amount of drug passes to fetus

23-May-2010

  

MTN-002 Backgrounder

23-May-2010

  

MTN-002 Q&A

23-May-2010

 

See Also

MTN-002 Protocol

 

MTN-002 Study Page

 

Trial is first to see if HIV prevention gels are safe for pregnant women & their babies

12-June-2008

  

MTN-016


Source URL: https://www.mtnstopshiv.org/news/mtn-002